Results 1 to 10 of about 122,669 (246)

Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

Journal of gastroenterology, 2021
Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike   +18 more
openalex   +2 more sources

Recent update: Nonalcoholic steatohepatitis

Journal of Marine Medical Society, 2018
Nonalcoholic fatty liver disease has been traditionally conceptualized as a histological disease spectrum which progresses from simple steatosis or pure fatty liver through liver fibrosis or Nonalcoholic Steatohepatitis (NASH) to cirrhosis and eventually
Vivek Hande, Jnanaprakash B Karanth, P C Hande   +2 more
doaj   +2 more sources

Necroptosis in Nonalcoholic Steatohepatitis [PDF]

Cellular and Molecular Gastroenterology and Hepatology, 2015
Jérémie Gautheron, PhD, Mihael Vucur, PhD, Tom Luedde MD,, PhD   +2 more
doaj   +2 more sources

P-80 SEVERELY OBESE PATIENTS HAD HEPATIC FIBROSIS EVEN WITHOUT METABOLIC SYNDROME

Annals of Hepatology, 2021
Introduction: Metabolic Associated Fatty Liver Disease (MAFLD) is a clinic-pathological condition commonly associated with metabolic syndrome (MS) and this association is frequently found in severely obese. Objective: To compare clinical and histological
Carla Daltro, Ana Paula Berbeth-Casto, Luiz Antonio R de-Freitas, Antônio Ricardo Andrade, Helma P. Cotrim   +4 more
doaj   +1 more source

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, 2023
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach.
Z. Younossi, P. Golabi, James M. Paik, Austin Henry, Catherine Van Dongen, L. Henry   +5 more
semanticscholar   +1 more source

O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT?

Annals of Hepatology, 2021
Background: The prevalence of metabolic associated fatty liver disease (MAFLD) in lean patients has grown around the world and the better understanding of this liver disease, in these individuals, has become of interest.
Andreza Rosa Cabral, Ana Rafaela S. Do Vale, Naiades S. Almeida, Raquel Rocha, Antonio Ricardo C.F. de Andrade, Ana Cristina Landin, Helma P. Cotrim   +6 more
doaj   +1 more source

P-83 RELEVANCE OF RENAL CHANGES IN A LARGE SERIES OF SEVERELY OBESE PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE

Annals of Hepatology, 2021
Introduction: Metabolic associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease worldwide. Recently, the relationship between MAFLD and chronic kidney disease has raised more interest because this relationship may be an ...
Kellyane Dias Carvalho, Carla Daltro, Claudia Daltro, Helma P. Cotrim   +3 more
doaj   +1 more source

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

Nature Network Boston, 2023
The FLIGHT-FXR trial, testing farnesoid X receptor agonist tropifexor in nonalcoholic steatohepatitis, demonstrated sustained decreases in alanine aminotransferase levels and hepatic fat fraction, but not aspartate aminotransferase, with dose-dependent ...
A. Sanyal, Patricia Lopez, E. Lawitz, K. Lucas, J. Loeffler, Won Kim, G. Goh, Jee‐Fu Huang, C. Serra, P. Andreone, Yi-Cheng Chen, S. Hsia, V. Ratziu, D. Aizenberg, Hiroshi Tobita, A. Sheikh, J. Vierling, Y. Kim, H. Hyogo, Dean Tai, Z. Goodman, F. Schaefer, I. R. Carbarns, S. Lamle, M. Martic, N. Naoumov, C. Brass   +26 more
semanticscholar   +1 more source

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

New England Journal of Medicine, 2020
BACKGROUND Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited.
P. Newsome, Kristine Buchholtz, K. Cusi, Martin Linder, T. Okanoue, V. Ratziu, A. Sanyal, A. Sejling, S. Harrison   +8 more
semanticscholar   +1 more source

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)

Biology, 2022
Simple Summary In the context of liver disease, one of the more growing public health problems is the transition from simple steatosis to non-alcoholic steatohepatitis.
S. Todisco, A. Santarsiero, Paolo Convertini, Giulio Francesco De Stefano, M. Gilio, V. Iacobazzi, V. Infantino   +6 more
semanticscholar   +1 more source